Other adverse outcomes like mucositis, constipation, and diarrhea (Primarily with the usage of specific agents) has to be detected early and handled vigorously as a way to obtain patient compliance. carriers may be greater candidates for therapy with single-agent PARP inhibitors than triple-negative breast cancer BRCA1 Trong bài viết https://peterx863qyf0.dm-blog.com/profile